



## Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma *in vitro* and *in vivo* by targeting the AKT signaling pathway

Piming Zhao<sup>1</sup> · Ana E. Aguilar<sup>1,2</sup> · Joanna Y. Lee<sup>1</sup> · Lucy A. Paul<sup>1</sup> · Jung H. Suh<sup>1</sup> · Latika Puri<sup>1,3</sup> · Meng Zhang<sup>1</sup> · Jennifer Beckstead<sup>1</sup> · Andrzej Witkowski<sup>1</sup> · Robert O. Ryan<sup>1</sup> · Julie D. Saba<sup>1</sup>

Published online: 29 April 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

**Correction to: Investigational New Drugs (2018) 36:743–754**  
<https://doi.org/10.1007/s10637-017-0558-5>

The authors would like to note an omission of disclosure in this paper. Author JDS is cofounder, equity-holder, and consultant of GILTRx Therapeutics.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s10637-017-0558-5>

---

✉ Julie D. Saba  
[jsaba@chori.org](mailto:jsaba@chori.org)

<sup>1</sup> UCSF Benioff Children's Hospital Oakland, Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, USA

<sup>2</sup> Present address: Arnold Palmer Hospital for Children, 92 W Miller St MP 318 2nd floor, Orlando, FL 32806, USA

<sup>3</sup> Present address: St Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA